Cardium Announces InnerCool's New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL cer...(ons andinvolve a variety of risks and un...)

Date:7/14/2008

ons and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that new marks and certifications, distribution agreements or other commercialization efforts will effectively accelerate InnerCool's patient temperature modulation business or market, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that our products or proposed products will prove to be sufficiently safe and effective, that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive, that results or trends observed in one clinical study will be reproduced in subsequent studies, that third parties on whom we depend will behave as anticipated, or that necessary regulatory approvals will be obtained. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development, testing and marketing of therapeutic hypothermia devices and the conduct of human clinical trials, including the timing, costs and outcomes of such trials, whether our efforts to launch new devices and systems and expand our markets will be successful or completed within the time frames contemplated, our dependence upon proprietary technology, our ability to obtain necessary funding, regulatory approvals and qualifications, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission
'/>"/>

SOURCE Cardium Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. Cardium Announces Follow-On Direct Investment by Institutional Investor
2. Cardium Selected for Inclusion in Russell Microcap Index
3. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
4. Cardium Launches New AWARE Clinical Study Website
5. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
6. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
7. Cardium Reports on First Quarter 2008 Highlights and Financial Results
8. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
9. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
10. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
11. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion